Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H + , K + - ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases. In Vitro The mechanism of action of Abeprazan is reversibly binding to H + , K + ‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Abeprazan inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Abeprazan
CAS number：1902954-60-2(DMSO) molecular formula：C19H17F3N2O3S
overview
compound introduction
Specs
| Chinese alias | 阿贝拉赞 | ||
| English alias | - | ||
| CAS number | 1902954-60-2(DMSO) | molecular formula | C19H17F3N2O3S |
| molecular weight | 410.41 g/mol | Exact mass | 10mM in DMSO |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
